{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:09:35Z","timestamp":1787497775958,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.10.038","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T06:53:55Z","timestamp":1762584835000},"page":"412-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploration of In Vivo T-cell Depletion protocols in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies"],"prefix":"10.1016","volume":"32","author":[{"given":"Hongru","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-5894","authenticated-orcid":false,"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2025.10.038_bib0001","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0002","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.038_bib0003","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"acute graft-versus-host disease \u2014 biologic process, prevention, and therapy. Longo DL, editor","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.038_bib0004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.038_bib0005","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0006","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.038_bib0008","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/bloodadvances.2020003779","article-title":"A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation","volume":"5","author":"Bejanyan","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.038_bib0009","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose post-transplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.038_bib0010","doi-asserted-by":"crossref","first-page":"3514.1","DOI":"10.1182\/blood-2024-198252","article-title":"OPTIMIZE: a phase II study of reduced dose post transplantation cyclophosphamide As GVHD prophylaxis in adult patients with hematologic malignancies receiving HLA-mismatched unrelated donor peripheral blood stem cell transplantation","volume":"144","author":"Auletta","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.038_bib0011","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jtct.2025.10.038_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.10.038_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-Host disease prophylaxis with cyclophosphamide and cyclosporin","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.038_bib0014","doi-asserted-by":"crossref","first-page":"576.e1","DOI":"10.1016\/j.jtct.2023.06.008","article-title":"Phase II study of myeloablative 7-8\/8-matched allotransplantation with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"29","author":"El Jurdi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.jtct.2025.10.038_bib0015","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program\u2013sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.10.038_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","author":"Al Malki","year":"2025","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.038_bib0017","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/bloodadvances.2024015173","article-title":"Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial","volume":"9","author":"Raiola","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0018","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor\u2013free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0019","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.27619","article-title":"Differential clinical and immunological impacts of Anti\u2013T-lymphocyte globulin (ATLG) versus. Anti-thymocyte globulin (ATG) in preventing graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: a comparative study","volume":"100","author":"Notarantonio","year":"2025","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.038_bib0020","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2006-04-019059","article-title":"Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity","volume":"108","author":"Blaser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.038_bib0021","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.3389\/fimmu.2018.03061","article-title":"Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80","volume":"9","author":"Cassady","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.038_bib0022","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI94196","article-title":"PD-L1 serves as a double agent in separating GVL from GVHD","volume":"127","author":"Brennan","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2010-07-294785","article-title":"Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL","volume":"118","author":"Hanash","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.038_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-017-0490-3","article-title":"Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation","volume":"10","author":"Tormo","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2025.10.038_bib0025","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.jtct.2025.10.038_bib0026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"issue":"29","key":"10.1016\/j.jtct.2025.10.038_bib0027","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.038_bib0028","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/ajh.26320","article-title":"Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.10.038_bib0030","doi-asserted-by":"crossref","unstructured":"Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. 2019 [cited 2025 Mar 12]; Available from: http:\/\/hdl.handle.net\/10668\/13498","DOI":"10.1016\/S2352-3026(18)30214-X"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0032","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.038_bib0033","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.038_bib0034","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti\u2013T-cell globulin ATG-Fresenius","volume":"117","author":"Soci\u00e9","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.038_bib0035","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"},{"issue":"36","key":"10.1016\/j.jtct.2025.10.038_bib0036","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of Anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease\u2013free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0037","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0038","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of thymoglobulin\u00ae in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.038_bib0039","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.038_bib0040","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0041","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","article-title":"Antithymocyte globulin exposure in CD34+ T-cell\u2013depleted allogeneic hematopoietic cell transplantation","volume":"6","author":"Lakkaraja","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0042","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.038_bib0043","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","article-title":"Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation","volume":"9","author":"Admiraal","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.038_bib0044","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ajh.27068","article-title":"Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.038_bib0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with thiotepa in T cell- replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors","volume":"24","author":"Dul\u00e9ry","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.038_bib0046","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-Intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.038_bib0047","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41409-020-0813-9","article-title":"Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD","volume":"55","author":"Salas","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0048","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41409-019-0726-7","article-title":"Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.038_bib0049","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41409-020-01047-2","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.10.038_bib0051","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.038_bib0052","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0053","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0054","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jtct.2024.07.017","article-title":"Combination of Anti-thymocyte globulin with post-transplant cyclophosphamide for GVHD prophylaxis in patients undergoing haploidentical hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"31","author":"Luo","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.10.038_bib0055","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: a systematic review and meta-analysis","volume":"13","author":"Tang","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0056","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00277-021-04399-x","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis","volume":"100","author":"Gao","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0057","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00277-025-06199-z","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis","volume":"104","author":"Jin","year":"2025","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1016\/j.jtct.2025.10.038_bib0058","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.038_bib0059","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ajh.25087","article-title":"Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European society for blood and marrow transplantation (EBMT) study","volume":"93","author":"Li","year":"2018","journal-title":"American J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.038_bib0060","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in haploidentical transplantation for relapsed\/refractory acute myeloid leukemia: a study from the acute leukemia working party of the EBMT","volume":"144","author":"Battipaglia","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0061","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-017-0480-5","article-title":"Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Santoro","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.038_bib0062","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia","volume":"106","author":"Nagler","year":"2020","journal-title":"haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0063","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3390\/cancers14041097","article-title":"Outcomes of different haploidentical transplantation strategies from the taiwan blood and marrow transplantation registry","volume":"14","author":"Tsai","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0064","first-page":"629","article-title":"Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese bone marrow transplantation registry group","volume":"110","author":"Xu","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0066","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0067","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18620\/ctt-1866-8836-2020-9-1-53-59","volume":"9","author":"Morozova","year":"2020","journal-title":"CTT"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.038_bib0068","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0069","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41409-019-0682-2","article-title":"Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation","volume":"55","author":"Nykolyszyn","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.038_bib0070","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0071","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.19031","article-title":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","volume":"203","author":"Aydin","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.038_bib0072","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","article-title":"Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.jtct.2025.10.038_bib0073","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.038_bib0074","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","article-title":"PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation","volume":"14","author":"Penack","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.038_bib0075","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","article-title":"ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.10.038_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.038_bib0077","first-page":"640","article-title":"Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study","volume":"110","author":"Kerbauy","year":"2024","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.jtct.2025.10.038_bib0078","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.038_bib0079","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.038_bib0080","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2020.271445","article-title":"Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation","volume":"107","author":"Massoud","year":"2021","journal-title":"haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:32:45Z","timestamp":1778355165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666636725015520"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.038","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of In Vivo T-cell Depletion protocols in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}